ClearLight Biotechnologies, LLC (ClearLight) (Formerly: ClearLight Diagnostics, LLC) Announces a Company Name Change and the Introduction of a Pilot Laboratory Service Model Based on the CLARITY Technology
SUNNYVALE, Calif., Oct. 23, 2018 /PRNewswire/ -- ClearLight Biotechnologies, LLC (ClearLight) (Formerly: ClearLight Diagnostics, LLC), a developer of an automated next generation tissue processing platform and proprietary 3D image analysis software for research and future diagnostic applications, announces a new company name and the introduction of a pilot lab service model.
Effective immediately, ClearLight announces a company name change to CLEARLIGHT BIOTECHNOLOGIES, LLC. The new name will drive awareness in the marketplace to accurately reflect the current short and longer-term business plan, as well as the future potential commercialization plan to introduce a Research Use Only (RUO) platform into the market. In parallel, ClearLight is pleased to announce their pilot custom laboratory services model. The services offered will include: CLARITY tissue clearing & immunostaining, 3D imaging (multiplexed fluorescence), and 3D image analysis and will be offered to key RUO markets (pharmaceutical and academics), for early adopters of the technology.
"We have been strategizing with the board of directors as well as our scientific advisors to reshape the business plan so that we are better equipped to take the company into the next phase of development," stated Laurie Goodman, Ph.D., CEO of ClearLight. "With our new pilot custom lab services offering, our goal is to begin to build a solid customer base as a means to inform the future commercialization strategy."
Please visit ClearLight's new website at: www.clearlightbiotechnologies.com
About ClearLight
Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an automated instrumentation platform based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and analysis of heterogeneous cellular interactions within the microenvironment of a tissue. This technology, paired with a multi-sample tissue imaging and proprietary 3D image analysis software, will enable more accurate analysis and assessment of normal and diseased tissue.
Visit us: www.clearlightbiotechnologies.com
Contact: Laurie Goodman, Ph.D., CEO
[email protected]
(800) 251-8905
SOURCE ClearLight Biotechnologies
Share this article